KAUST
King Abdullah University of Science and Technology (KAUST) has recently wrapped up 'Destination Deep Tech,' a Saudi-first program that spins in leading-edge global startups to the Kingdom to develop deep tech innovations. The international startups - CeEntek , Hopu , Insignes-Labs , Pasqal , and Proteinea - were chosen to experience the three-month program as a result of their highly advanced technology expansion into the MENA region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005518/en/
“KAUST is the Deep Tech Heart of the Saudi Economy, and so we are delighted to welcome these talented international startups to KAUST and the Kingdom as part of Destination Deep Tech,” said Dr. Kevin Cullen, Vice President of KAUST Innovation.
Pasqal, from France, is a leading European Quantum Computing startup that provides a full-stack solution from hardware to applications. Their goal is to bring the quantum advantage faster to end-users. Pasqal has recently signed an MoU with Aramco and is currently looking to establish a commercial presence in the region.
Insignes-Labs, from Poland, develops antimicrobial additives to protect a wide range of materials from microorganisms such as bacteria, algae, fungi and molds. The company is currently running a pilot program with KAUST startup Red Sea Farms while applying for a KAUST Technology Transfer Impact Acceleration Fund to further collaborate with the University and bring the product to market.
Proteinia, from Egypt, is a platform technology that harnesses the power of AI, deep learning models and biological automation for protein design and production. By fast-tracking the commercialization of key optimized protein products, Proteinia aims to serve the areas of human health, aquaculture industries, and sustainable food technologies.
CeEntek, from Singapore, delivers Ultra-High Performance Concrete for increased sustainability and efficiency of construction projects. Their innovative manufacturing process allows for UHPC 2.0™ concrete solutions in a wide range of markets and applications.
Hopu, from Spain, provides AI-based IoT devices and sensors for Industry 4.0 and Smart Cities, covering air quality monitoring, noise, energy metering and more. The company is deploying its air quality sensors in the KAUST network through a collaboration with KAUST Smart and KAUST academics.
The Next Web (TNW) is the team behind Destination Deep Tech. It helps corporations and governments to innovate together with the startup ecosystem and ensured that top talent was recruited for the program.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005518/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ookla Unveils Speedtest Pulse™, Redefining Network Validation and Troubleshooting10.11.2025 12:00:00 CET | Press release
Disruptive new diagnostic device puts 20 years of network expertise in the hands of ISPs and enterprises, empowering them to validate performance, end costly repeat visits, and boost customer satisfaction. Ookla®, a global leader in connectivity intelligence, today unveiled Speedtest Pulse™, a new network diagnostic device designed to provide definitive, smartphone-based validation and troubleshooting for internet service providers (ISPs) and enterprises. Leveraging the power of Speedtest®, a globally trusted gold standard for connectivity measurement, Speedtest Pulse bridges a crucial gap in technician toolkits, offering a powerful, scalable solution that is easy to use and provides clear, actionable insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110605367/en/ Speedtest Pulse™ is a dual-mode network diagnostic tool offering one-tap, smartphone-based validation and troubleshooting, and autonomous testing of netw
Kaneka Expands Global Reach with i-ED COIL™ Launch in Europe10.11.2025 03:51:00 CET | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has begun sales of its i-ED COIL™, a brain aneurysm embolization coil (*1), in Europe as of October. The product obtained EC certification (*2) under an EU Medical Device Regulation (*3) in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251109744229/en/ i-ED Coil The i-ED COIL™ provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week8.11.2025 23:15:00 CET | Press release
- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerular filtration rate across both diseases - - Vertex on track to initiate rolling submission of Biologics License Application for potential accelerated approval to the U.S. Food and Drug Administration this year; full enrollment completed for Phase 3 RAINIER trial in IgA nephropathy - - Povetacicept in primary membranous nephropathy granted Fast Track Designation by the U.S. Food and Drug Administration and Phase 2/3 pivotal trial initiated - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual
Westinghouse and Hungary Establish Landmark Nuclear Fuel Partnership8.11.2025 15:00:00 CET | Press release
First Contract Signed with MVM Group to Deliver VVER-440 Fuel to Paks Nuclear Power Plant Westinghouse Electric Company and MVM Group signed a contract to ensure diversification of fuel supply in Hungary. This partnership brings to Paks Nuclear Power Plant (NPP) reliable supply with Westinghouse VVER fuel, manufactured in Europe. The Westinghouse VVER-440 fuel reload deliveries will start in 2028, subject to licensing activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107682814/en/ Westinghouse Nuclear Fuel Senior Vice President Aziz Dag, left, and Károly Mátrai, CEO of the MVM Group, signed the Paks VVER-440 contract, Nov. 7, 2025. “Our agreement with Westinghouse is a clear response to today's energy challenges and further strengthens the role of Hungary's leading base power plant in the domestic energy supply. This strategically important step will make the operation of Paks Nuclear Power Plant safer and more f
OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”8.11.2025 07:00:00 CET | Press release
OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, OMRON has been implementing a Structural Reform Program “NEXT 2025” aimed at rebuilding our foundation for profitability and growth. With the completion of this Program in September 2025, we have shifted into a growth phase and formulated a new Roadmap looking ahead to 2030. This Roadmap identifies Business Portfolio Restructuring as a core strategy. We have defined Thirteen Focus Businesses to drive the Group’s future growth. By accelerating our selection and concentration efforts, we aim to build a “distinctive” business portfolio that maximizes overall Group growth. Furthermore, to maximize the growth potential of our Focus Busines
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom